Cargando…

Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function

SIMPLE SUMMARY: Pulmonary hypertension is a potentially life-threatening disease among dogs that is characterized by increased pulmonary arterial pressure and pulmonary vascular resistance. In veterinary medicine, a phosphodiesterase-5 inhibitor such as sildenafil is the most common drug used to tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Ryohei, Yuchi, Yunosuke, Saito, Takahiro, Yasumura, Yuyo, Teshima, Takahiro, Matsumoto, Hirotaka, Koyama, Hidekazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405226/
https://www.ncbi.nlm.nih.gov/pubmed/36009668
http://dx.doi.org/10.3390/ani12162078
_version_ 1784773829012226048
author Suzuki, Ryohei
Yuchi, Yunosuke
Saito, Takahiro
Yasumura, Yuyo
Teshima, Takahiro
Matsumoto, Hirotaka
Koyama, Hidekazu
author_facet Suzuki, Ryohei
Yuchi, Yunosuke
Saito, Takahiro
Yasumura, Yuyo
Teshima, Takahiro
Matsumoto, Hirotaka
Koyama, Hidekazu
author_sort Suzuki, Ryohei
collection PubMed
description SIMPLE SUMMARY: Pulmonary hypertension is a potentially life-threatening disease among dogs that is characterized by increased pulmonary arterial pressure and pulmonary vascular resistance. In veterinary medicine, a phosphodiesterase-5 inhibitor such as sildenafil is the most common drug used to treat pulmonary hypertension. However, the availability of sildenafil is limited because of its high cost, difficulty in obtaining the drug in some areas, and potential inter-individual variability in the response to sildenafil therapy. Beraprost sodium is one of the most common drugs used to treat pulmonary hypertension in humans. However, little is known about its efficacy in dogs with pulmonary hypertension. In this study, beraprost sodium showed significant pulmonary and systemic vasodilation without any adverse effects in sixteen dogs with pulmonary hypertension. Additionally, echocardiographic improvements in cardiac function and pulmonary and systemic circulation were observed. These results emphasize the potential efficacy of beraprost sodium in treating canine pulmonary hypertension. ABSTRACT: Pulmonary hypertension (PH) is a fatal condition that affects many dogs. In humans, PH is often treated with beraprost sodium (BPS). However, the effectiveness of BPS for canine PH has not been established. This study aimed to evaluate the clinical and cardiovascular response of BPS in canine patients with PH of various causes. Sixteen dogs with PH (post-capillary PH, n = 8; pre-capillary PH, n = 8) were included. BPS was continuously administered twice daily at 15 µg/kg. All dogs underwent echocardiography, including speckle-tracking analysis and blood pressure measurement, before and after BPS administration. Continuous BPS administration (range: 13.2–22.0 µg/kg) significantly decreased the pulmonary and systemic vascular impedance and increased left and right ventricular myocardial strain. In dogs with post-capillary PH, BPS administration caused no significant worsening of the left atrial pressure indicators. No side effects of BPS were observed in any dog. BPS also improved cardiac function and pulmonary circulation through pulmonary vasodilation, suggesting that BPS may be an additional treatment option for canine PH of various causes. Particularly, BPS increased left ventricular function and systemic circulation without worsening the left heart loading condition in dogs with post-capillary PH.
format Online
Article
Text
id pubmed-9405226
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94052262022-08-26 Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function Suzuki, Ryohei Yuchi, Yunosuke Saito, Takahiro Yasumura, Yuyo Teshima, Takahiro Matsumoto, Hirotaka Koyama, Hidekazu Animals (Basel) Article SIMPLE SUMMARY: Pulmonary hypertension is a potentially life-threatening disease among dogs that is characterized by increased pulmonary arterial pressure and pulmonary vascular resistance. In veterinary medicine, a phosphodiesterase-5 inhibitor such as sildenafil is the most common drug used to treat pulmonary hypertension. However, the availability of sildenafil is limited because of its high cost, difficulty in obtaining the drug in some areas, and potential inter-individual variability in the response to sildenafil therapy. Beraprost sodium is one of the most common drugs used to treat pulmonary hypertension in humans. However, little is known about its efficacy in dogs with pulmonary hypertension. In this study, beraprost sodium showed significant pulmonary and systemic vasodilation without any adverse effects in sixteen dogs with pulmonary hypertension. Additionally, echocardiographic improvements in cardiac function and pulmonary and systemic circulation were observed. These results emphasize the potential efficacy of beraprost sodium in treating canine pulmonary hypertension. ABSTRACT: Pulmonary hypertension (PH) is a fatal condition that affects many dogs. In humans, PH is often treated with beraprost sodium (BPS). However, the effectiveness of BPS for canine PH has not been established. This study aimed to evaluate the clinical and cardiovascular response of BPS in canine patients with PH of various causes. Sixteen dogs with PH (post-capillary PH, n = 8; pre-capillary PH, n = 8) were included. BPS was continuously administered twice daily at 15 µg/kg. All dogs underwent echocardiography, including speckle-tracking analysis and blood pressure measurement, before and after BPS administration. Continuous BPS administration (range: 13.2–22.0 µg/kg) significantly decreased the pulmonary and systemic vascular impedance and increased left and right ventricular myocardial strain. In dogs with post-capillary PH, BPS administration caused no significant worsening of the left atrial pressure indicators. No side effects of BPS were observed in any dog. BPS also improved cardiac function and pulmonary circulation through pulmonary vasodilation, suggesting that BPS may be an additional treatment option for canine PH of various causes. Particularly, BPS increased left ventricular function and systemic circulation without worsening the left heart loading condition in dogs with post-capillary PH. MDPI 2022-08-15 /pmc/articles/PMC9405226/ /pubmed/36009668 http://dx.doi.org/10.3390/ani12162078 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Suzuki, Ryohei
Yuchi, Yunosuke
Saito, Takahiro
Yasumura, Yuyo
Teshima, Takahiro
Matsumoto, Hirotaka
Koyama, Hidekazu
Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function
title Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function
title_full Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function
title_fullStr Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function
title_full_unstemmed Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function
title_short Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function
title_sort beraprost sodium for pulmonary hypertension in dogs: effect on hemodynamics and cardiac function
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405226/
https://www.ncbi.nlm.nih.gov/pubmed/36009668
http://dx.doi.org/10.3390/ani12162078
work_keys_str_mv AT suzukiryohei beraprostsodiumforpulmonaryhypertensionindogseffectonhemodynamicsandcardiacfunction
AT yuchiyunosuke beraprostsodiumforpulmonaryhypertensionindogseffectonhemodynamicsandcardiacfunction
AT saitotakahiro beraprostsodiumforpulmonaryhypertensionindogseffectonhemodynamicsandcardiacfunction
AT yasumurayuyo beraprostsodiumforpulmonaryhypertensionindogseffectonhemodynamicsandcardiacfunction
AT teshimatakahiro beraprostsodiumforpulmonaryhypertensionindogseffectonhemodynamicsandcardiacfunction
AT matsumotohirotaka beraprostsodiumforpulmonaryhypertensionindogseffectonhemodynamicsandcardiacfunction
AT koyamahidekazu beraprostsodiumforpulmonaryhypertensionindogseffectonhemodynamicsandcardiacfunction